Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy
Top Cited Papers
Open Access
- 1 February 2019
- journal article
- review article
- Published by Informa UK Limited in Therapeutics and Clinical Risk Management
- Vol. ume 15, 323-335
- https://doi.org/10.2147/tcrm.s150524
Abstract
With immunotherapy innovations for cancer treatment, in particular chimeric antigen receptor (CAR) T cells, becoming more successful and prevalent, strategies to mitigate and manage their toxicities are required. Anti-CD19 CAR T-cell therapy has revolutionized the treatment of relapsed/refractory pediatric and adult acute lymphoblastic leukemia and refractory adult non-Hodgkin lymphoma, resulting in the expanded use of CAR T cells in multicenter trials and as US FDA-approved products. Cytokine release syndrome (CRS) and CAR-associated neurotoxicity, which can occur independently or concurrently with CRS, are two potentially life-threatening toxicities of CAR T-cell therapy. In this review, we will focus on describing the pathophysiology behind CRS, the proposed definitions of and grading systems for CRS, and innovative options for treating this potentially lethal systemic inflammatory condition.Keywords
This publication has 33 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic LeukemiaScience Translational Medicine, 2013
- The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood CancerClinical Cancer Research, 2012
- Identification of Cell Surface Proteins as Potential Immunotherapy Targets in 12 Pediatric CancersFrontiers in Oncology, 2012
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6International Journal of Biological Sciences, 2012
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008
- Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group studyBlood, 2008
- How I treat patients with diffuse large B-cell lymphomaBlood, 2007
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412The New England Journal of Medicine, 2006
- Treatment of Adult Acute Lymphoblastic LeukemiaHematology, 2006